Archived Monthly Oncology Tumor Boards: Treatment of Patients with Bladder and Upper Tract Urothelial Cancer

The recent approvals of nivolumab for adjuvant treatment of urothelial carcinoma who are at high risk of recurrence following radical resection and the antibody-drug conjugates enfortumab vedotin-ejfv and sacituzumab govitecan-hziy for previously treated metastatic urothelial cancer represent substantial updates to the treatment of urothelial bladder and upper tract tumors. Clinicians can find it difficult to stay current on these updates. Education on the appropriate use of these therapies and considerations for treatment planning and side effect management can benefit clinicians interested in incorporating these therapies into their clinical practice.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the results of recent clinical trials for treatment of non-muscle invasive bladder cancer and their potential impact on treatment of BCG-unresponsive disease.
  • Describe new and emerging systemic therapy options for patients with muscle-invasive or metastatic urothelial bladder cancer and how patient and disease characteristics can guide therapy choice.
  • Review how antibody-drug conjugates may be incorporated into treatment planning for previously treated metastatic urothelial carcinoma.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Coherus BioSciences
  • Exact Sciences
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Lilly
  • Novartis

This activity is supported by independent educational grants from:

  • Merck & Co., Inc.
  • Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

This educational activity is supported by medical education grants from:

  • Exelixis, Inc.
  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
10/06/2022
Course expires: 
10/06/2023
Cost:
$0.00
Part of: 
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care

Jean Hoffman-Censits, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Max Kates, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Steven Rowe, MD, PhD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Jean Hoffman-Censits, MD
Genentech, Inc.: Grant/Research Support
Ikena Oncology: Grant/Research Support
QED Therapeutics, Inc.: Grant/Research Support
SeaGen: Grant/Research Support; Scientific Advisor

Max Kates, MD
Astellas Pharma US, Inc.: Consulting Fee
Genesis Therapeutics, Inc.: Consulting Fee
NanOlogy, LLC: Consulting Fee
Photocure ASA: Consulting Fee

Steven Rowe, MD, PhD
Lantheus Pharmaceuticals, Inc.: Consulting Fee; Grant/Research Support; Product/Speakers Bureau
PlenaryAI, Inc.: Consulting Fee; Equity Interest/Stock Options; Grant/Research Support; Intellectual Property Rights
Precision Molecular, Inc.: Consulting Fee; Equity Interest/Stock Options; Grant/Research Support; Intellectual Property Rights

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-22-106-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 6, 2023. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: I00052159; Approval #: 220003005

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing